Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma.
Jaume MoraAlicia CastañedaMaria Cecilia ColomboMaite GorosteguiFernando Gómez MuñozSalvador MañeVicente Santa-MariaMoira GarrausNapoleon MaciasSara Perez-JaumeOscar MuñozJuan Pablo Muñoz PérezIgnasi BarberMariona SuñolPublished in: Cancers (2021)
Our results disclose an undescribed mechanism of action for naxitamab and highlight the limitations of conventional imaging in the evaluation of anti-GD2 immunotherapy clinical efficacy for HR-NB.